Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 13 of 13

List	Outcome	Time frame
Primary	Proportion of participants with confirmed objective response to Tarlatamab	Approximately 52 Months
Primary	Proportion of participants with complete response to Tarlatamab	Approximately 52 Months
Primary	Proportion of participants with partial response to Tarlatamab	Approximately 52 Months
Secondary	Average serum concentrations of Tarlatamab	Approximately 52 Weeks
Secondary	Duration of confirmed response, defined as the time from the first documentation of OR until the first documentation of disease progression or death	Approximately 52 Months
Secondary	Disease control, defined as objective response or stable disease	Approximately 52 Months
Secondary	Duration of disease control	Approximately 52 Months
Secondary	Progression-free survival, defined as the time from randomization to the first documentation of disease progression or death due to any cause	Approximately 52 Months
Secondary	Objective response, defined as best overall response of CR or PR	Approximately 52 Months
Secondary	Overall survival, defined as the time from randomization to death due to any cause	Approximately 52 Months
Secondary	Overall Survival rate at 6 months and 1 year from randomization	Approximately 52 Months
Secondary	Number of participants with treatment-emergent adverse events	Approximately 52 Months
Secondary	Number of participants with anti-tarlatamab antibody formation	Approximately 52 Months

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06745323/registered